ABSTRACT:
Considerable research interest has been directed toward 1,8-naphthyridine-based compounds owing to their extensive pharmacological versatility, especially their notable antimycobacterial efficacy. The aim of this research is to study how changes at the C6 and C7 positions of the 2-piperidin-1-yl-substituted 1,8-naphthyridine structure influence its effectiveness against Mycobacterium tuberculosis in vitro. The chemical structures of the synthesized compounds were validated using a combination of spectroscopic characterization techniques and elemental analysis to confirm molecular composition. An initial in vitro screening of all synthesized compounds was performed against Mycobacterium tuberculosis H37Rv at a standardized test concentration of 6.25µg/mL. The minimum inhibitory concentrations (MICs) were evaluated only for compounds that demonstrated =90% growth inhibition in the initial screen. Some of the tested compounds exhibited activity against M. tuberculosis H37Rv in vitro, with several performing comparably to the MIC of the reference drug rifampicin. Analogues labeled V through X demonstrated satisfactory anti-tubercular potential, with those featuring a methoxy group at the C7 position of the 1,8-naphthyridine backbone exhibiting pronounced antimycobacterial effectiveness. Notably, compound X, which has 6-amino and 7-methoxy groups, was the most promising antitubercular agent against M. tuberculosis H37Rv in vitro, with a minimum inhibitory concentration (MIC) of 0.38µg/mL, compared to the reference rifampicin with an MIC value of 0.31µg/mL.
Cite this article:
Jalal Aljamal. Antimycobacterial Activity Evaluations of Novel 2-piperidin-1-yl-1,8-Naphthyridine Analogues. Research Journal of Pharmacy and Technology. 2026;19(8):3610-6. doi: 10.52711/0974-360X.2026.00510
Cite(Electronic):
Jalal Aljamal. Antimycobacterial Activity Evaluations of Novel 2-piperidin-1-yl-1,8-Naphthyridine Analogues. Research Journal of Pharmacy and Technology. 2026;19(8):3610-6. doi: 10.52711/0974-360X.2026.00510 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-8-27
REFERENCES:
1. Gradmann C. Robert Koch and the pressures of scientific research: tuberculosis and tuberculin. Med Hist. 2001; 45(1): 1–32. doi:10.1017/S0025727300000028.
2. Sagavkar SR, Devkar SR. Tuberculosis: a review. Asian J Pharm Res. 2018; 8(3): 191–4. doi:10.5958/2231-5691.2018.00033.3.
3. Napier G, Campino S, Merid Y, et al. Robust barcoding and identification of Mycobacterium tuberculosis lineages for epidemiological and clinical studies. Genome Med. 2020; 12: 114. doi:10.1186/s13073-020-00817-3.
4. Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Disease control priorities, 3rd edition (Vol. 6): Major infectious diseases. 2017: 233–313. doi:10.1596/978-1-4648-0524-0_ch11.
5. Floyd K, Glaziou P, Zumla A, et al. The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respir Med. 2018; 6(4): 299–314. doi:10.1016/S2213-2600(18)30057-2.
6. Gordon SV, Parish T. Microbe profile: Mycobacterium tuberculosis – humanity’s deadly microbial foe. Microbiology. 2018; 164(4): 437–9. doi:10.1099/mic.0.000601.
7. World Health Organization. Global tuberculosis report 2023. Geneva: WHO; 2023. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023.
8. World Health Organization. Global tuberculosis report 2024. Geneva: WHO; 2024. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024.
9. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13(10):e1002152. doi:10.1371/journal.pmed.1002152.
10. Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV coinfection. Cold Spring Harb Perspect Med. 2015;5(7):a017871. doi:10.1101/cshperspect.a017871.
11. Gopalan N, Chandrasekaran P, Swaminathan S, et al. Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Res Ther. 2016; 13: 45. doi:10.1186/s12981-016-0118-7.
12. Schön T, Miotto P, Köser CU, et al. Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives. Clin Microbiol Infect. 2017; 23(3): 154–60. doi:10.1016/j.cmi.2016.10.022.
13. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in rural South Africa. Lancet. 2006; 368(9547): 1575–80. doi:10.1016/S0140-6736(06)69573-1.
14. Viney K, Linh NN, Gegia M, et al. New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization. Eur Respir J. 2021; 57(4): 2003752. doi:10.1183/13993003.00361-2021.
15. Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med. 2020; 8(1): 19. doi:10.1016/S2213-2600(19)30418-7.
16. Bandgar HR. Side effects of TB therapy and recent therapeutic approaches for tuberculosis management. Asian J Pharm Res. 2023; 13(1): 31–3. doi:10.52711/2231-5691.2023.00005.
17. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010; 375(9728): 1830–43. doi:10.1016/S0140-6736(10)60410-2.
18. Rahim MA, Seo H, Barman I, et al. Insights into autophagy in microbiome therapeutic approaches for drug-resistant tuberculosis. Cells. 2025; 14(7): 540. doi:10.3390/cells14070540.
19. Kufa M, Arora N, Govender T, et al. Revolutionizing tuberculosis treatment: breakthroughs and future directions in anti‑TB drug discovery. Molecules. 2025; 30(12): 2443. doi:10.3390/molecules30122443.
20. Agnivesh PK, Roy A, Sau S, et al. Advancements and challenges in tuberculosis drug discovery: A comprehensive overview. Microb Pathog. 2025; 198: 107074. doi: 10.1016/j.micpath.2024.107074.
21. Jain SD, Prachand S, Gupta AK, et al. Fluoroquinolones for the treatment of tuberculosis: an overview. Asian J Res Pharm Sci. 2023; 13(4): 333–7. doi:10.52711/2231-5659.2023.00057.
22. Wójcicka A, Mączyński M. Antimicrobial activity of naphthyridine derivatives. Pharmaceuticals. 2024; 17(12): 1705. doi:10.3390/ph17121705.
23. Mithula S, Nandikolla A, Murugesan S, et al. 1,8-naphthyridine derivatives: recent advancements and biological activities. Future Med Chem. 2021;13(18):1591–618. doi:10.4155/fmc-2021-0086.
24. Domala R, Butti AR, Eppakayla L. Study of antifungal activity of 2-methyl-3-(5'-aryl/aryloxymethyl-1',3',4'-oxadiazol-2'-yl) amino-1,8-naphthyridines. Res J Pharm Technol. 2022; 15(2): 757–60. doi:10.52711/0974-360X.2022.00126.
25. Nadaraj V, Selvi ST. Synthesis and characterization of naphtho fused [1,8] naphthyridine derivatives. Asian J Res Chem. 2011;4(1):28–30. Available from: https://ajrconline.org/AbstractView.aspx?PID=2011-4-1-4.
26. Badawneh M, Manera C, Mori C, et al. Synthesis of variously substituted 1,8-naphthyridine derivatives and evaluation of their antimycobacterial activity. Farmaco. 2002; 57(8): 631–9. doi:10.1016/S0014-827X(02)01235-1.
27. Badawneh M, Aljamal J. Synthesis and antitubercular activity of piperidine and morpholine 1,8-naphthyridine analogues. Int J Pharm Pharm Sci. 2016; 8(12): 252–6. doi:10.22159/ijpps.2016v8i12.13503.
28. Badawneh M, Bellini L, Cavallini T, Aljamal JA, et al. Synthesis of phenyl-1,8-naphthyridine derivatives and evaluation of antimycobacterial and antimicrobial activity. Farmaco. 2003; 58(9): 859–66. doi:10.1016/S0014-827X(03)00144-7.
29. Sandhya G, Sravanthi GG. Microwave-assisted synthesis of 1,3,5-triazine containing [1,8] naphthyridine derivatives. Asian J Res Chem. 2018; 11(1): 109–10. doi:10.5958/0974-4150.2018.00022.6.
30. Gallo JF, Pinhata JMW, Saraceni CP, et al. Evaluation of the BACTEC MGIT 960 system and the resazurin microtiter assay for susceptibility testing of Mycobacterium tuberculosis. J Microbiol Methods. 2017; 139: 168–71. doi:10.1016/j.mimet.2017.06.007.
31. Yu HJ, Lee H, Lee D, et al. Performance evaluation of the BACTEC MGIT 960 system with revised critical concentrations for rifampicin resistance detection. J Clin Microbiol. 2023; 61(7): e01086‑22. doi:10.1128/jcm.01086‑22.
32. Genestet C, Ader F, Pichat C, et al. Assessing the combined antibacterial effect of isoniazid and rifampin on M. tuberculosis strains using in vitro response-surface modeling. Antimicrob Agents Chemother. 2018; 62(1): e01413-17. doi:10.1128/AAC.01413-17.
33. Ghosh MK, Khan MRI, Rony SR, Mukherjee B, Uddin MKM, Banu S, Barman RK. Design, optimization and in vitro assessment of rifampicin-loaded self-nanoemulsifying drug delivery system. Res J Pharm Technol. 2025; 18(5): 2023–31. doi:10.52711/0974-360X.2025.00289.
34. Ghasemi M, Liang S, Luu QM, et al. The MTT assay: a method for error minimization and interpretation in measuring cytotoxicity. Methods Mol Biol. 2023; 2644: 15–33. doi:10.1007/978-1-0716-3052-5_2.
35. Aljamal JA, Badawneh M. Characterization of the biochemical effects of new 1,8-naphthyridine derivatives, β-receptor antagonists, in ventricular myocytes. Arch Pharm (Weinheim). 2003; 336(6–7): 285–92. doi:10.1002/ardp.200300781.
36. Capela R, Félix R, Clariano M, et al. Target identification in anti-tuberculosis drug discovery. Int J Mol Sci. 2023; 24(13): 10482. doi:10.3390/ijms241310482.
37. Patel RG, Patel CK, Panigrahi B, et al. Tuberculosis: pathophysiology, diagnosis and antitubercular activity of actinomycin from new Streptomyces species. Res J Pharmacol Pharmacodyn. 2010; 2(1): 23–6. Available from: https://rjppd.org/AbstractView.aspx?PID=2010-2-1-25.
38. Goossens SN, Sampson SL, Van Rie A. Mechanisms of drug-induced tolerance in Mycobacterium tuberculosis. Clin Microbiol Rev. 2020; 34(1): e00141-20. doi:10.1128/CMR.00141-20.
39. Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015; 5(9): a017863. doi:10.1101/cshperspect.a017863.
40. Sivakumar S, Sangeetha D. Identification of new inhibitor against M. tuberculosis using structure-based docking. Res J Pharmacognosy Phytochem. 2017; 9(3): 173–6. doi:10.5958/0975-4385.2017.00032.2.
41. Martolia J, Soni H, Tandel F. Natural perspective for management of drug-resistant tuberculosis: a review. Res J Pharm Technol. 2020; 13(8): 4002–8. doi:10.5958/0974-360X.2020.00708.8.
42. Khetmalis YM, Shobha S, Nandikolla A, et al. Design, synthesis, and anti‑mycobacterial evaluation of 1,8‑naphthyridine‑3‑carbonitrile analogues. RSC Adv. 2024; 14: 22676–22690. doi:10.1039/D4RA04262J.